1185 related articles for article (PubMed ID: 20394870)
1. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
Gajos G; Rostoff P; Undas A; Piwowarska W
J Am Coll Cardiol; 2010 Apr; 55(16):1671-8. PubMed ID: 20394870
[TBL] [Abstract][Full Text] [Related]
2. Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism.
Gajos G; Zalewski J; Nessler J; Zmudka K; Undas A; Piwowarska W
Kardiol Pol; 2012; 70(5):439-45. PubMed ID: 22623230
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization.
Gao P; Xiong H; Zheng Z; Li L; Gao R; Hu SS
Platelets; 2010; 21(3):183-90. PubMed ID: 20201634
[TBL] [Abstract][Full Text] [Related]
4. Soluble P-selectin level correlates with acetylsalicylic acid but not with clopidogrel response in patients with stable coronary artery disease after a percutaneous coronary intervention.
Kaufmann J; Wellnhofer E; Kappert K; Urban D; Meyborg H; Hauptmann T; Müller A; Meixner M; Graf K; Fleck E; Stawowy P
Coron Artery Dis; 2013 Jun; 24(4):312-20. PubMed ID: 23549485
[TBL] [Abstract][Full Text] [Related]
5. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.
Ueno M; Ferreiro JL; Tomasello SD; Tello-Montoliu A; Capodanno D; Seecheran N; Kodali M; Dharmashankar K; Desai B; Charlton RK; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2011 Aug; 4(8):905-12. PubMed ID: 21851906
[TBL] [Abstract][Full Text] [Related]
6. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
Aleil B; Jacquemin L; De Poli F; Zaehringer M; Collet JP; Montalescot G; Cazenave JP; Dickele MC; Monassier JP; Gachet C
JACC Cardiovasc Interv; 2008 Dec; 1(6):631-8. PubMed ID: 19463377
[TBL] [Abstract][Full Text] [Related]
7. Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot).
Gajos G; Zalewski J; Rostoff P; Nessler J; Piwowarska W; Undas A
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1696-702. PubMed ID: 21617138
[TBL] [Abstract][Full Text] [Related]
8. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
[TBL] [Abstract][Full Text] [Related]
9. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation.
Siller-Matula JM; Haberl K; Prillinger K; Panzer S; Lang I; Jilma B
Thromb Res; 2009 Apr; 123(6):874-80. PubMed ID: 19135705
[TBL] [Abstract][Full Text] [Related]
10. Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading.
Kim IS; Jeong YH; Tantry US; Park Y; Lee DH; Bliden KP; Koh JS; Park JR; Jang JS; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S; Gurbel PA
Am Heart J; 2013 Jul; 166(1):95-103. PubMed ID: 23816027
[TBL] [Abstract][Full Text] [Related]
11. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
[TBL] [Abstract][Full Text] [Related]
13. Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study.
Park Y; Jeong YH; Tantry US; Ahn JH; Kim KH; Koh JS; Park JR; Hwang SJ; Kwak CH; Hwang JY; Gurbel PA
Thromb Haemost; 2014 Dec; 112(6):1198-208. PubMed ID: 25182660
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Yokoi H; Kimura T; Isshiki T; Ogawa H; Ikeda Y
Thromb Res; 2012 May; 129(5):623-8. PubMed ID: 22178576
[TBL] [Abstract][Full Text] [Related]
15. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
Stellbaum C; Ayral Y; Morguet A; Schultheiss HP; Rauch U
Cardiovasc Revasc Med; 2012; 13(3):159-66. PubMed ID: 22503564
[TBL] [Abstract][Full Text] [Related]
16. The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity.
Gremmel T; Kopp CW; Seidinger D; Giurgea GA; Koppensteiner R; Steiner S; Panzer S
Atherosclerosis; 2009 Dec; 207(2):608-13. PubMed ID: 19616779
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox".
Motovska Z; Widimsky P; Petr R; Bilkova D; Marinov I; Simek S; Kala P;
J Cardiovasc Pharmacol; 2009 May; 53(5):368-72. PubMed ID: 19247187
[TBL] [Abstract][Full Text] [Related]
18. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Steinhubl SR; Berger PB; Mann JT; Fry ET; DeLago A; Wilmer C; Topol EJ;
JAMA; 2002 Nov; 288(19):2411-20. PubMed ID: 12435254
[TBL] [Abstract][Full Text] [Related]
19. N-3 polyunsaturated fatty acids do not influence the efficacy of dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention.
Mizia-Stec K; Mizia M; Haberka M; Lasota B; Gieszczyk-Strózik K; Chmiel A; Najda J; Gąsior Z; Kyrcz-Krzemień S
Cardiol J; 2013; 20(5):478-85. PubMed ID: 24469870
[TBL] [Abstract][Full Text] [Related]
20. Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: beyond aspirin and clopidogrel.
Cohen MG; Rossi JS; Garbarino J; Bowling R; Motsinger-Reif AA; Schuler C; Dupont AG; Gabriel D
Thromb Res; 2011 Oct; 128(4):335-40. PubMed ID: 21621252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
